Skip to content
10-K

Annual Report

Cadrenal Therapeutics, Inc. CVKD

0001213900-26-036946

← back to feed
Filed
Mar 31, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 27, 2026 2.51M sh
Shares Diluted FY 2025 · Dec 31, 2025 1.99M sh
Shares Diluted FY 2025 · Dec 31, 2024 1.22M sh
Capex FY 2025 · Dec 31, 2025 $5.1K
Capex FY 2025 · Dec 31, 2024 $6.54K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$12.6M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$7.36M
Cash And Equivalents FY 2025 · Dec 31, 2025 $4.01M
Cash And Equivalents restated FY 2025 · Dec 31, 2024 $10.02M
Stockholders Equity FY 2025 · Dec 31, 2025 $2.74M
Stockholders Equity FY 2025 · Dec 31, 2024 $7.44M
Stockholders Equity FY 2025 · Dec 31, 2023 $7.69M
Current Liabilities FY 2025 · Dec 31, 2025 $1.59M
Current Liabilities FY 2025 · Dec 31, 2024 $2.68M
Total Liabilities FY 2025 · Dec 31, 2025 $1.59M
Total Liabilities FY 2025 · Dec 31, 2024 $2.68M
Current Assets FY 2025 · Dec 31, 2025 $4.32M
Current Assets FY 2025 · Dec 31, 2024 $10.11M
Total Assets FY 2025 · Dec 31, 2025 $4.33M
Total Assets FY 2025 · Dec 31, 2024 $10.12M
Eps Diluted FY 2025 · Dec 31, 2025 −$6.64
Eps Diluted FY 2025 · Dec 31, 2024 −$8.73
Eps Basic FY 2025 · Dec 31, 2025 −$6.64
Eps Basic FY 2025 · Dec 31, 2024 −$8.73
Sga Expense FY 2025 · Dec 31, 2025 $9.35M
Sga Expense FY 2025 · Dec 31, 2024 $6.75M
Rd Expense FY 2025 · Dec 31, 2025 $4.1M
Rd Expense FY 2025 · Dec 31, 2024 $4.21M
Net Income FY 2025 · Dec 31, 2025 −$13.24M
Net Income FY 2025 · Dec 31, 2024 −$10.65M
Operating Income FY 2025 · Dec 31, 2025 −$13.46M
Operating Income FY 2025 · Dec 31, 2024 −$10.96M